Emergent BioSolutions Secures $250M in Government Contract, Announces Strategic Moves Including Sale Of Baltimore Site to Boost Cash Generation and Slash Debt by $100M
Emergent BioSolutions Secures $250M in Government Contract, Announces Strategic Moves Including Sale Of Baltimore Site to Boost Cash Generation and Slash Debt by $100M
Emergent BioSolutions Inc. (NYSE:EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This disciplined approach has enhanced Emergent's financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue strategic initiatives.
Emergent BioSolutions Inc. (紐交所：EBS)今天強調了其在改善財務狀況方面的幾項最新進展，以強勁的現金生成和有意義的債務償還爲標誌。根據其未來幾年轉型公司的運營計劃，Emergent正努力執行其策略，以提高運營效率，簡化成本，產生現金以增加盈利能力並減少公司總債務。這種有紀律的方法不僅增強了Emergent的財務狀況，還使公司成爲以客戶爲重點的、更精簡、更靈活的組織，豐富了追求戰略計劃的機會。
Emergent's recent actions include:
Emergent的最新動作包括:
- Secured $250 million in U.S. government contract award modifications for four medical countermeasures
- Announced a $30 million definitive agreement to sell its Baltimore-Camden manufacturing site, which is expected to close in the third quarter of 2024, subject to the satisfaction or waiver of customary closing conditions
- Received $7 million for sale of its unimproved, empty building in Canton, Massachusetts
- As disclosed yesterday in its SEC filing, the resolution of its contract dispute with Janssen Pharmaceuticals, Inc., including the impending receipt of $50 million in the third quarter of this year
- Expected receipt of a development milestone payment as part of its Travel Health Business sale by year end
- 爲四種醫療應對措施（countermeasures）獲得了2.5億美元的美國政府合同獎勵改進。
- 宣佈以3千萬美元的價格出售其位於巴爾的摩-卡姆登（Baltimore-Camden）的製造廠，預計在2024年第三季度完成，取決於滿足或放棄慣常的結束條件。
- 以700萬美元的價格出售位於馬薩諸塞州康頓（Canton）的未開發、空置建築。
- 正如昨天在其SEC申報中披露的，Emergent與Janssen Pharmaceuticals，Inc.的合同爭議得到了解決，包括今年第三季度即將收到5千萬美元的款項。
- 預計到年底，作爲其旅行健康業務出售的一部分，將收到開發里程碑付款。
"Emergent is making steady progress toward cash generation and debt repayment, which is in service to our strategic plan to stabilize our financial position and ultimately transform the organization as we continue to be a global leader in public health preparedness," said Joe Papa, president and CEO of Emergent. "We remain committed to reaching our target of more than $100 million in debt reduction this year, while continuing to deliver vital medicines to our customers and patients, creating long-term and sustainable value for shareholders and working toward strengthening our balance sheet, so that we have a healthier financial foundation to support our company's future direction."
“Emergent正在穩步向現金生成和債務償還邁進，以服務於我們的戰略計劃，以穩定我們的財務狀況，最終改造組織，繼續成爲全球公共衛生準備工作的領導者，” Emergent的總裁兼首席執行官喬·帕帕表示，“我們仍然致力於實現今年10,000萬美元以上的債務減少目標，同時繼續向客戶和患者提供重要藥物，爲股東創造長期和可持續的價值，努力加強資產負債表，以便我們擁有更健康的財務基礎，支持公司未來的方向。”
Emergent will provide more on its 2024 financial outlook, incorporating any potential expectations related to these recent events, and other relevant information when it reports its second quarter financial results in August.
Emergent將在8月份公佈第二季度業績時，提供有關2024年財務前景、這些最新事件和其他相關信息的更多信息。